Trial Profile
A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of Loncastuximab Tesirine and Ibrutinib in Patients With Advanced Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma (LOTIS-3)
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 12 Feb 2024
Price :
$35
*
At a glance
- Drugs Ibrutinib (Primary) ; Loncastuximab tesirine (Primary)
- Indications Diffuse large B cell lymphoma; Mantle-cell lymphoma
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms LOTIS 3
- Sponsors ADC Therapeutics
- 30 Mar 2023 The trial has been completed in Belgium, according to Eudra record.
- 31 Jan 2023 Status changed from active, no longer recruiting to discontinued.
- 22 Jul 2022 Planned End Date changed from 28 Apr 2023 to 15 Nov 2022.